Official Title
Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients
Brief Summary

This is a research that will investigate the safety and efficacy of virgin coconut oil(VCO) as an adjunctive therapy for Coronavirus Disease 2019 (COVID-19)

Detailed Description

This study will be a randomized controlled trial among hospitalized COVID-19 patients,
aged 18 years old and above, admitted at the Philippine General hospital. Patients will
be grouped into the following:

1. Group receiving standard of care

2. Group receiving standard of care plus virgin coconut oil (15ml, 3x/day for 2 weeks)
as adjunctive therapy.

Patients will be observed as regards to primary outcomes such as recovery/resolution of
symptoms and duration of hospital stay

Unknown status
COVID19

Drug: Virgin Coconut Oil

Oral supplementation of virgin coconut oil to COVID-19 patients
Other Name: VCO

Eligibility Criteria

Inclusion Criteria:

- symptomatic and asymptomatic COVID-19 hospitalized patients

- has laboratory-confirmed illness during the time of recruitment

- able to take food and medicines enterally

Exclusion Criteria:

- uncontrolled or newly diagnosed diabetes mellitus

- with chronic heart disease

- having elevated lipid profile at baseline (admission)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Philippines
Locations

Philippine General Hospital
Manila, Metro Manila, Philippines

University of the Philippines
NCT Number
Keywords
virgin coconut oil
COVID19
MeSH Terms
COVID-19